Free Trial

Ovid Therapeutics (OVID) Institutional Ownership

Ovid Therapeutics logo
$2.80 -0.01 (-0.18%)
As of 03:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Institutional Ownership Changes (13F Filings) for Ovid Therapeutics (NASDAQ:OVID)

Current
Institutional Ownership
Percentage
72.24%
Number of
Institutional Buyers
(last 12 months)
40
Total
Institutional Inflows
(last 12 months)
$68.43M
Number of
Institutional Sellers
(last 12 months)
19
Total
Institutional Outflows
(last 12 months)
$10.54M
Get OVID Insider Trade Alerts

Want to know when executives and insiders are buying or selling Ovid Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Chart & View Institutional Buying and Selling Data

OVID Institutional Buying and Selling by Quarter

Ovid Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/14/2026Sei Investments Co.328,924$730K0.0%N/A0.249%
5/14/2026 Walleye Capital LLC443,362$984K0.0%-16.3%0.336%
5/14/2026State of Wyoming22,171$49K0.0%N/A0.017%
4/27/2026 Simplify Asset Management Inc.130,813$290K0.0%N/A0.099%
4/20/2026 Assenagon Asset Management S.A.227,742$506K0.0%-63.1%0.173%
4/17/2026 Total Clarity Wealth Management Inc.20,975$47K0.0%-26.7%0.016%
4/17/2026 Sovereign Financial Group Inc.30,000$67K0.0%+200.0%0.023%
2/19/2026 Invesco Ltd.33,308$54K0.0%N/A0.047%
2/18/2026ADAR1 Capital Management LLC4,285,000$6.99M0.5%+33,256.7%6.017%
2/18/2026Ikarian Capital LLC247,558$404K0.0%-77.4%0.348%
2/18/2026Quadrature Capital Ltd87,874$143K0.0%+217.2%0.123%
2/18/2026Millennium Management LLC1,339,465$2.18M0.0%+35.8%1.881%
2/18/2026Balyasny Asset Management L.P.325,000$530K0.0%-48.0%0.456%
2/18/2026Boothbay Fund Management LLC155,741$254K0.0%-68.0%0.219%
2/17/2026ADAR1 Capital Management LLC4,285,000$6.99M0.5%+33,256.7%6.017%
2/17/2026Schonfeld Strategic Advisors LLC192,496$314K0.0%-78.2%0.270%
2/17/2026Ally Bridge Group NY LLC1,785,000$2.91M3.0%N/A2.507%
2/17/2026RA Capital Management L.P.10,714,000$17.46M0.2%N/A15.046%
2/17/2026Adage Capital Partners GP L.L.C.3,492,000$5.69M0.0%+158.7%4.904%
2/17/2026Graham Capital Management L.P.127,459$208K0.0%N/A0.179%
2/16/2026Squarepoint Ops LLC39,034$64K0.0%-66.0%0.055%
2/16/2026OMERS ADMINISTRATION Corp125,300$204K0.0%N/A0.176%
2/16/2026Eventide Asset Management LLC4,285,000$6.99M0.1%N/A6.017%
2/13/2026Marshall Wace LLP1,271,487$2.07M0.0%+62.3%1.786%
2/13/2026 Walleye Capital LLC530,020$864K0.0%-11.2%0.744%
2/13/2026Affinity Asset Advisors LLC7,150,000$11.65M0.7%+169.8%10.041%
2/13/2026AWM Investment Company Inc.899,200$1.47M0.1%N/A1.263%
2/13/2026State Street Corp276,533$451K0.0%+21.8%0.388%
2/13/2026 Wells Fargo & Company MN720,848$1.18M0.0%-1.4%1.012%
2/12/2026 Jane Street Group LLC883,867$1.44M0.0%+270.7%1.241%
2/12/2026Renaissance Technologies LLC1,484,478$2.42M0.0%-26.4%2.085%
2/12/2026 Federated Hermes Inc.3,571,000$5.31M0.0%N/A5.015%
2/11/2026 LPL Financial LLC30,000$49K0.0%+150.0%0.042%
2/10/2026Goldman Sachs Group Inc.170,457$278K0.0%+497.7%0.239%
2/9/2026Geode Capital Management LLC672,004$1.10M0.0%+3.7%0.944%
2/2/2026 Total Clarity Wealth Management Inc.28,600$47K0.0%N/A0.040%
1/12/2026 Benin Management CORP19,000$31K0.0%N/A0.027%
1/9/2026 Assenagon Asset Management S.A.618,019$1.01M0.0%-33.2%0.868%
11/17/2025Qube Research & Technologies Ltd25,277$33K0.0%-65.3%0.035%
11/17/2025Parkman Healthcare Partners LLC202,978$264K0.0%N/A0.285%
Peptide Company Lands Exclusive MMA Wellness Partnership (Ad)

A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform tied to Conor McGregor and Dana White - reaching millions of combat sports and biohacking followers worldwide. On April 15, RFK Jr. announced the FDA would remove 12 peptides from restricted Category 2 status. This company was already selling products tied to three of those peptides - and has developed a patent-pending transdermal patch addressing the 63.2% of adults with needle phobia. The peptide therapeutics market is projected to reach $294 billion by 2033.tc pixel

Read the full report on this small-cap peptide company now
11/17/2025Millennium Management LLC986,293$1.28M0.0%-6.3%1.385%
11/17/2025Integrated Wealth Concepts LLC52,900$69K0.0%N/A0.074%
11/17/2025Bank of America Corp DE362,707$472K0.0%+2,333.0%0.509%
11/17/2025Boothbay Fund Management LLC486,877$633K0.0%N/A0.684%
11/14/2025Schonfeld Strategic Advisors LLC883,154$1.15M0.0%N/A1.240%
11/14/2025Two Sigma Investments LP341,134$443K0.0%N/A0.480%
11/14/2025Squarepoint Ops LLC114,923$149K0.0%-48.0%0.162%
11/13/2025Kennedy Capital Management LLC1,106,638$1.44M0.0%-26.3%1.556%
11/13/2025 Private Advisor Group LLC25,600$33K0.0%N/A0.036%
11/10/2025 Persistent Asset Partners Ltd46,040$60K0.0%N/A0.065%
11/7/2025 GSA Capital Partners LLP265,993$346K0.0%-64.2%0.374%
11/7/2025Vanguard Group Inc.2,820,813$3.67M0.0%+7.0%3.967%
11/4/2025TLS Advisors LLC18,858$26K0.1%-97.2%0.027%
10/17/2025 Apollon Wealth Management LLC27,500$36K0.0%N/A0.039%
10/7/2025 Assenagon Asset Management S.A.924,576$1.20M0.0%+112.2%1.300%
8/15/2025Rosalind Advisors Inc.500,000$165K0.1%N/A0.703%
8/15/2025Rubric Capital Management LP478,533$158K0.0%-91.0%0.673%
8/14/2025 Jane Street Group LLC142,597$47K0.0%N/A0.201%
8/14/2025Velan Capital Investment Management LP160,000$53K0.1%+64.9%0.225%
8/13/2025Marshall Wace LLP164,721$54K0.0%N/A0.232%
8/13/2025Kennedy Capital Management LLC1,502,329$496K0.0%-13.3%2.113%
8/8/2025Geode Capital Management LLC643,335$212K0.0%-51.7%0.905%
8/1/2025 Y Intercept Hong Kong Ltd160,306$53K0.0%N/A0.225%
7/11/2025 Assenagon Asset Management S.A.435,620$144K0.0%-22.3%0.613%
6/27/2025Goldman Sachs Group Inc.104,435$33K0.0%-47.3%0.147%
5/21/2025Acadian Asset Management LLC2,088,046$650K0.0%+12.8%2.936%
5/16/2025Goldman Sachs Group Inc.104,435$33K0.0%-47.3%0.147%
5/16/2025Jacobs Levy Equity Management Inc.200,593$63K0.0%-31.2%0.282%
5/16/2025Adage Capital Partners GP L.L.C.1,150,000$359K0.0%+15.0%1.617%
5/14/2025Affinity Asset Advisors LLC667,516$208K0.0%N/A0.939%
5/12/2025Nuveen LLC119,113$37K0.0%N/A0.168%
5/8/2025XTX Topco Ltd93,154$29K0.0%N/A0.131%
4/15/2025Assenagon Asset Management S.A.560,830$175K0.0%+699.9%0.789%
2/17/2025Velan Capital Investment Management LP70,000$65K0.1%N/A0.099%
2/17/2025Madison Avenue Partners LP3,722,627$3.48M0.4%-9.6%5.242%
2/17/2025OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC943,416$881K0.1%+50.2%1.329%
2/17/2025Jacobs Levy Equity Management Inc.291,701$272K0.0%N/A0.411%
2/17/2025Bridgeway Capital Management LLC229,115$214K0.0%-26.0%0.323%
2/17/2025Bank of America Corp DE56,733$53K0.0%+49.7%0.080%
2/17/2025BNP Paribas Financial Markets104,712$98K0.0%-52.5%0.147%
2/14/2025Adage Capital Partners GP L.L.C.1,000,000$934K0.0%N/A1.408%
2/13/2025Kennedy Capital Management LLC1,545,387$1.44M0.0%+1.1%2.176%
2/13/2025Renaissance Technologies LLC107,700$101K0.0%+142.0%0.152%
2/13/2025ADAR1 Capital Management LLC130,532$122K0.0%+245.8%0.184%
2/12/2025TLS Advisors LLC680,967$636K1.5%-11.7%0.959%
2/12/2025Takeda Pharmaceutical Co. Ltd.7,531,996$7.01M26.4%N/A10.607%
2/12/2025JPMorgan Chase & Co.1,418,306$1.32M0.0%-3.1%1.997%
2/10/2025Monimus Capital Management LP138,266$129K0.1%N/A0.195%
1/30/2025Rhumbline Advisers84,078$79K0.0%+22.3%0.118%
1/17/2025SG Americas Securities LLC37,636$35K0.0%+83.9%0.053%
Before you buy SpaceX shares, consider this alternative approach (Ad)

SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel

Discover the overlooked SpaceX IPO strategy before the June listing
1/14/2025Assenagon Asset Management S.A.70,114$65K0.0%-18.7%0.099%
11/19/2024Barclays PLC84,175$98K0.0%+311.2%0.119%
11/16/2024Geode Capital Management LLC1,317,330$1.56M0.0%+1.1%1.855%
11/15/2024Barclays PLC84,175$98K0.0%+311.2%0.119%
11/15/2024XTX Topco Ltd38,230$45K0.0%+46.2%0.054%
11/15/2024Jane Street Group LLC38,399$45K0.0%-61.1%0.054%
11/14/2024Verition Fund Management LLC74,875$88K0.0%N/A0.105%
11/13/2024BNP Paribas Financial Markets220,401$260K0.0%+4,128.7%0.311%
11/13/2024FMR LLC50,225$59K0.0%+1,907.4%0.071%
11/5/2024GSA Capital Partners LLP260,509$307K0.0%+118.0%0.367%


OVID Institutional Ownership - Frequently Asked Questions

During the previous two years, 73 institutional investors and hedge funds held shares of Ovid Therapeutics. The most heavily invested institutionals were RA Capital Management L.P. ($17.46M), BVF Inc. IL ($11.75M), Affinity Asset Advisors LLC ($11.65M), Takeda Pharmaceutical Co. Ltd. ($7.01M), ADAR1 Capital Management LLC ($6.99M), Eventide Asset Management LLC ($6.99M), and Adage Capital Partners GP L.L.C. ($5.69M).Learn more on Ovid Therapeutics' institutional investors.

72.24% of Ovid Therapeutics' stock is owned by institutional investors. Learn more on OVID's institutional investor holdings.

Of the 59 institutional investors that purchased Ovid Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($10.71M), ADAR1 Capital Management LLC ($8.64M), Takeda Pharmaceutical Co. Ltd. ($7.53M), Affinity Asset Advisors LLC ($5.17M), Eventide Asset Management LLC ($4.29M), Federated Hermes Inc. ($3.57M), and Adage Capital Partners GP L.L.C. ($3.29M).

Institutional investors have bought a total of 43,561,841 shares in the last 24 months. This purchase volume represents approximately $68.43M in transactions.

Of the 19 institutional investors that sold Ovid Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Rubric Capital Management LP ($4.84M), Ikarian Capital LLC ($848.02K), Assenagon Asset Management S.A. ($822.04K), Schonfeld Strategic Advisors LLC ($690.66K), Geode Capital Management LLC ($687.66K), TLS Advisors LLC ($662.11K), and Kennedy Capital Management LLC ($626.23K).

Institutional investors have sold a total of 11,559,956 shares in the last 24 months. This volume of shares sold represents approximately $10.54M in transactions.



This page (NASDAQ:OVID) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners